Recent advances in exacerbations of COPD

Thorax

Volumn 63, Issue 10, 2008, Pages 850-852

  Seemungal, Terence ^a,b,c   Sykes, Annemarie ^a,b  

^a ICEAD Contributors ^*

^b UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM; ANTIBIOTIC AGENT; ARFORMOTEROL; FORMOTEROL; INDACATEROL; LEUKOTRIENE B4; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; PLACEBO; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EDITORIAL; EXPERIMENTAL STUDY; HEALTH; MIXED INFECTION; MORTALITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; SYMPTOM; VIRUS;

EID: 53649093994     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2008.099127     Document Type: Editorial

References (43)

1. Stark JE, Heath RB, Curwen MP. Infection with influenza and parainfluenza viruses in chronic bronchitis. Thorax 1965;20:124-7.
2. McHardy VU, Inglis JM, Calder MA. et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest 1980;74:228-38.
3. Seemungal T, Donaldson GC. Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
4. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
5. Wedzicha JA, Calverley PMA, Seemungal TAR, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2007;177:19-26.
6. Rodriguez-Roisin R, Toward a consensus definition for COPD exacerbations. Chest 2000;117(Suppl 2):398S-401.
7. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Summary of GOLD recommendations, with citations from the scientific literature. Revised 2006. http://www.goldcopd.com/Guidelineitem.asp?11=2&12=1&intld=996 (accessed 7 July 2008).
8. Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-20.
9. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003;58:680-5.
10. Soler-Cataluña JJ, Martínez-García MAMÁ. Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
11. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006;100:115-22.
12. Nurmagaenbetov T, Atherly A, Williams S. et al. What is the cost to employers of direct medical care for chronic obstructive pulmonary disease? COPD 2006;3:203-9.
13. Seemungal TAR, Harper-Owen R, Bhowmik A, et al. Respiratory viruses and symptoms, inflammatory markers in acute exacerbations of COPD. Am J Respir Crit Care Med 2001;164:1618-23.
14. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21.
15. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71.
16. Chin CL, Manzel LJ, Lehman EE. et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91.
17. Seemungal TAR, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease, Eur Respir J 2000;16:677-83.
18. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59.
19. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
20. Perera WR, Hurst JR, Wilkinson TMA, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007;29:527-34.
21. Wilkinson TMA, Donaldson GC, Johnston SL et al. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:871-6.
22. Hurst JR, Perera WR. Wilkinson TMA, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:71-8.
23. Abe Y, Murphy TF, Sethi S, et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:967-71.
24. O'Donnell DE, Parker CM. COPD exacerbations 3: Pathophysiology. Thorax 2006;61:354-61.
25. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-9.
26. Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968-75.
27. Watanabe T, Jono H, Han J, et al. Synergistc activation of NF-κB by nontypeable Haemophilus influenzae and tumor necrosis factor-alpha. PNAS 2004;101:3563-8.
28. Caramon G, Romagnoli M. Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 2003;58:348-51.
29. Cosio BG, Tsaprouni L, Ito K. et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-95.
30. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-76.
31. Maziak W, Loukides S. Culpitt S. et al. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:998-1002.
32. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M. et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: A randomized placebo-controlled trial. Pulm Pharmacol Ther 2008 Feb 21 (Epub ahead of print).
33. Krug N, Larbig M. Bonner J. et al. Anti-MCP-1-monoclonal antibody (ABN912) attenuates LPS-induced monocyte recruitment into the lung in patients with COPD. Proc Am Thorac Soc 2006;3:A849.
34. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-7.
35. Aaron SD, Vandemheen KL, Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348: 2618-25.
36. Dimopouios G, Piagnerelli M, Berre J, et al. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003;15:71-5.
37. Ram FSF, Rodriguez-Roisin R, Granados-Navarette A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; CD004403.
38. Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;1:CD001288.pub2.
39. Ito K, Lim S, Caramon G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Nati Acad Sci U S A 2002;99:8921-6.
40. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
41. Hatzehnann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
42. Smith SJ, Fenwick PS, Nicholson AG, et al. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006;149:393-404.
43. Beeh KM, Kommann O. Buhl R. et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interteukin-8 and leukotriene B4. Chest 2003;123:1240-7.